Pharma Focus Asia
KP - Sustainable Packaging Solutions

Novo Nordisk Invests US$134 million (DKK 950 million) for New Cell Therapy Facility in Denmark, Europe


Novo Nordisk plans to invest US$134 million (DKK 950 million) to open world-class cell facility located at Denmark, Europe.


The facility will serve as a pivotal large-scale production site, unifying a comprehensive array of expertise and services within a single location.

The facility will support various cell therapy types, encompassing those derived from embryonic stem cells, induced pluripotent stem cells, and adult stem cells. 

It will offer an extensive spectrum of services ranging from process development to product GMP manufacturing, product release, and regulatory assistance.

There will be built-in flexibility that can easily switch between different types of therapies and services to keep up with the fast-changing needs of the field. 

Construction of the facility is slated to commence in the summer of 2024, with the facility projected to become operational by 2027.


Name   Novo Nordisk
Type   New Construction
Budget US$134 million (DKK 950 million)
Year   2027

Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024CPHI Chine || PMEC China 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024CPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?